

Egetis Therapeutics - De-risked orphan play at a discount

Redeye updates its view of Egetis following a change of lead analyst and an eventful year, including a de-risked strategy to market and upcoming regulatory filings. We still see significant upside in Egetis and view this as a compelling investment case as we head into an momentous 2023.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Egetis Therapeutics - De-risked orphan play at a discount](#)